



12 - 23 - 02

G7
JAN 6 2003
CASE 4-30970A
w/attach

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV195226720 US

Express Mail Label Number

12/20/02

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 26 2002

IN RE PCT NATIONAL STAGE APPLICATION OF
CUENOUD ET AL.

Art Unit: 1614 TECH CENTER 1600/2900

INTERNATIONAL APPLICATION NO: PCT/EP00/05058
FILED: 2 JUNE 2000
U.S. APPLICATION NO: 10/009,008
35 USC §371 DATE: 8 JANUARY 2002
FOR: BETA2-ADRENOCEPTOR AGONISTSAssistant Commissioner for Patents
Washington, D.C. 20231SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Carol A. Loeschorn
Attorney for Applicants
Reg. No. 35,590

Novartis Pharmaceuticals Corporation
Corporate Intellectual Property
One Health Plaza
East Hanover, NJ 07936-1080
(862) 778-7881

Date: Dec. 20, 2002